|

Breast Cancer Clinical Trials in Colorado Springs, CO

26 recruiting studies within 50 miles

Phase
Trial Phase Dist.
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast CancerN/A<1 mi
Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN TrialsN/A<1 mi
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast CancerPhase 3<1 mi
Mobile Health for Adherence in Breast Cancer PatientsN/A<1 mi
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus TrastuzumabPhase 3<1 mi
Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer SurvivorsN/A<1 mi
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25Phase 3<1 mi
A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast CancerPhase 1/2<1 mi
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac ToxicityPhase 3<1 mi
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection—<1 mi
Improving Care for Rural Patients With Solid TumorsN/A<1 mi
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus PembrolizumabPhase 3<1 mi
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)Phase 3<1 mi
The PREDICT Registry:—<1 mi
Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast CancerPhase 3<1 mi
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast CancerPhase 3<1 mi
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics—<1 mi
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the BrainPhase 3<1 mi
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of RecurrencePhase 347 mi
A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)Phase 350 mi
Study of INCB123667 in Subjects With Advanced Solid TumorsPhase 150 mi
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast CancerPhase 1/250 mi
The Immune System's Response to Young Women's Breast Cancer—50 mi
Breast Cancer Patient Engagement With Patient Reported Outcome Measure SurveyN/A50 mi
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast CancerPhase 350 mi
The Vanguard Study: Testing a New Way to Screen for CancerN/A50 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.